The ability to induce protection against a genital challenge was studied in BALB/c female mice with three Chlamydia trachomatis mouse pneumonitis ( 
Pelvic inflammatory disease (PID) is a major health problem throughout the world (10, 16, 31, (43) (44) (45) . For example, in the United States, it is estimated that approximately 1 million women experience an episode of PID and that of these women, 200,000 are hospitalized yearly (10) . In addition to the health problem, this creates an enormous economic burden, so it is not surprising that for the year 2000, the costs related to the care of individuals with PID has been projected to reach $10 billion in the United States (42) .
Among the different microorganisms involved in PID, Chlamydia trachomatis plays a key role in a large number of cases (10, 31, 44, 45) . The prevalence of chlamydial infections in Western countries has been estimated to range from 3 to 5% in asymptomatic women to 20 to 30% in women attending clinics for sexually transmitted diseases. In most areas of the world, C. trachomatis is the most common sexually transmitted bacterial pathogen and affects the female population mainly during its reproductive years (4, 6, 7, 31, (43) (44) (45) . Approximately 4 million chlamydial infections occur in the United States on a yearly basis; 2.6 million affect women, 1.8 million affect men, and the rest involve infants (43) . C. trachomatis can produce a wide range of clinical infections, including cervicitis and salpingitis in women, urethritis and epididymitis in men, and conjunctivitis and pneumonia in children (31) . Although in most instances C. trachomatis produces a self-limited infection, in certain individuals the disease leads to chronic sequelae. Among the major complications that have been frequently associated with a C. trachomatis infection are tubal infertility, ectopic pregnancy, and chronic abdominal pain (4, 6, 16, 27, 31, 44, 45) . Furthermore, over 50% of the infections in females are asymptomatic, and thus only preventive therapy can be effective against this disease (2, 12, 14, 16, 17, 41) . As a result, there is a great need to develop a vaccine to prevent the transmission of C. trachomatis.
The major outer membrane protein (MOMP) of C. trachomatis has been considered by several authors to be the most likely candidate for an acellular vaccine (2, 14, 34, 41) . Studies
The animals were housed in isolation cubicles at a constant temperature of 24°C with a cycle of 12 h of light and 12 h of darkness and were fed mouse chowder ad libitum. All animal protocols were approved by the University of California, Irvine, Animal Care and Use Committee.
Mice were immunized with the different C. trachomatis MoPn MOMP preparations as follows. Mice were inoculated twice subcutaneously with 10 g of SDS-MOMP, OGP-MOMP, or Z3-14-MOMP the first time with complete Freund's adjuvant and the second time 2 weeks later with incomplete Freund's adjuvant. The COMC preparation was adsorbed with 0.3% aluminium hydroxide solution (Serva GmbH & Co., Heidelberg, Germany) and mixed at a 1:1 ratio with incomplete Freund's adjuvant (38) . Mice were boosted twice with the same dose at 2-week intervals. All the groups of mice were challenged on the 6th week after the first immunization. The positive control mice were inoculated intranasally with 10 4 C. trachomatis MoPn inclusion-forming units (IFU), and the negative controls received 10 g of ovalbumin by the same protocol as the one used for the animals immunized with the MOMP preparations. Each time a MOMP preparation was tested, a positive control-mice immunized intranasally with C. trachomatis MoPn EB-and a negative control-mice inoculated with 10 g of ovalbumin-were included in the study. A sham-immunized, nonchallenged group was included as a fertility control. All the experiments were repeated two or three times over a 3-year period. For data analysis, all the results obtained with the positive and negative control groups were added and used for statistical analyses.
For intrabursal inoculation, the animals were anesthetized with methoxyflurane and a lateral abdominal incision was made. The experimental group received 10 5 C. trachomatis MoPn IFU in 20 l of SPG in the left ovarian bursa and mock-infected HeLa-229 cell extracts processed by the same protocol used to purify the EB in the right ovarian bursa (22, 37) .
Six weeks after the intrabursal challenge, groups of four female mice were caged with a proven breeder male mouse for 18 days. Pregnancy was assessed by determining the increase in weight of the female mice starting at 10 to 12 days postmating as previously described (22) . Animals that did not become pregnant were mated a second time (22) .
Vaginal cultures. For the isolation of C. trachomatis MoPn, vaginal swabs were collected at regular intervals following the challenge. The specimens were cultured in McCoy cells grown in 24-well plates that were centrifuged at 1,000 ϫ g for 1 h at room temperature (21, 22) . At 48 h after inoculation, the monolayers were washed with PBS and fixed with methanol. The chlamydial inclusions were stained as previously described with a rabbit polyclonal anti-C. trachomatis MoPn serum prepared in our laboratory (21, 22) .
Immunoassays. Blood was collected by periorbital or heart puncture, and the serum was separated by centrifugation and pooled for each group of animals. Vaginal washes were collected by irrigation of the vagina twice with 20 l of PBS and were pooled for each group (11) . All immunoassays were performed with the pooled serum and vaginal washes from each group. The C. trachomatis MoPnspecific antibody titer in serum and vaginal washes was determined by an enzyme-linked immunosorbent assay (ELISA) as previously described (21, 22) . Briefly, 96-well plates were coated with C. trachomatis MoPn EB in PBS at a concentration of 10 g/ml, and 100 l of serum or 50 l of vaginal wash was added per well in twofold serial dilutions. After incubation at 37°C for 1 h and washing, the enzyme immunoassay plates were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG, IgG1, IgG2a, IgG2b, IgG3, IgM, or IgA (Southern Biotechnology Associates, Inc., Birmingham, Ala.). The binding was measured in an ELISA reader (Bio-Rad Laboratories, Richmond, Calif.). For color development, 2,2Ј-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) was used as the substrate.
The ability of the serum to neutralize the infectivity of C. trachomatis MoPn EB in vitro was determined as follows (26) . C. trachomatis MoPn (10 4 IFU) was added to serial dilutions of the serum made with 5% guinea pig sera in PBS. After incubation at 37°C for 45 min, the mixture was inoculated by centrifugation onto HeLa-229 cells (22, 26) . The monolayers were incubated for 24 h at 37°C in Eagle's minimal essential medium supplemented with 10% fetal bovine serum, gentamicin (50 g/ml), and cycloheximide (1 g/ml). The preparations were fixed with methanol and stained with a rabbit polyclonal anti-C. trachomatis MoPn serum and a goat anti-rabbit peroxidase stain. IFU were counted at a magnification of ϫ200, and the 50% inhibition was calculated based on the sera from the animals inoculated with ovalbumin.
For Western blotting, C. trachomatis MoPn EB and the affinity-purified 60-kDa heat shock protein (hsp), kindly supplied by R. Morrison, (Rocky Mountain Laboratory, Hamilton, Mont.), were resolved by 10% tricine-SDS-polyacrylamide gel electrophoresis (32) . Approximately 250 g of purified EB was loaded on a 7.5-cm-wide slab gel. Following transfer to nitrocellulose membranes, the nonspecific sites were blocked with BLOTTO (Bovine Lacto Transfer Technique Optimizer: 5% [wt/vol] nonfat dried milk, 2 mM CaCl 2 , and 50 mM Tris HCl [pH 8.0]), and the serum samples, diluted 1:200, were incubated at room temperature. The antibody binding was detected using horseradish peroxidase-conjugated goat anti-mouse antibody developed with 0.01% hydrogen peroxide and 4-chloro-1-napthol (21, 22) .
A kit (Cambridge Research Biochemical, Cambridge, England) based on the technique developed by Geysen et al. (15) was used to map the binding sites of the mouse antibodies on overlapping octameric peptides representing the C. trachomatis MoPn MOMP amino acid sequence (13) . Goat anti-mouse IgG conjugated to horseradish peroxidase served as the secondary antibody. The reactions were measured 1 h after ABTS was added by an ELISA reader equipped with a 405-nm filter.
Lymphocyte proliferation assay. To perform this assay, the spleens of two to four mice from each group were collected, teased, and enriched for T cells by passage over a nylon wool column. Accessory cells for antigen presentation were prepared by irradiating (3,000 rads; 137 Cs) syngenic unseparated spleen cells and incubating them at various ratios with C. trachomatis MoPn EB, and the lymphocyte proliferation assay was performed as previously described (21, 22 
RESULTS

Characterization of the vaccine candidate preparations.
A silver-stained gel of the four vaccine candidates is shown in Fig.  1 . The preparations extracted with the SDS, OGP, and Z3-14 detergents showed predominantly a single band corresponding to the MOMP (40 kDa). In the COMC preparation, the MOMP, a doublet corresponding to the 60-kDa cysteine-rich protein (crp), and a band at 28 kDa were the main components observed. In addition, other bands with molecular masses of 100 kDa or higher were noted in the COMC lane.
Immune response to the vaccine preparations. Overall there was a high antibody response in the serum and vaginal washes for the four preparations used as immunogens. In Table 1 , the data collected the day before the intrabursal challenge are shown. In general, the highest antibody serum levels to EB were observed in the mice inoculated with OGP-MOMP, while the lowest antibody response was obtained in the animals immunized with SDS-MOMP. Total antichlamydial serum IgG levels ranged from a titer of 51,200 in the animals immunized with OGP-MOMP to a titer of 12,800 in the mice immunized with SDS-MOMP. The distribution of antibody titer among the different IgG subclasses was similar among the four preparations, with the exception that the IgG2a levels obtained with SDS-MOMP and Z3-14-MOMP (100 and 200, respectively) were lower than those obtained with OGP-MOMP and COMC (6,400 and 6,500, respectively). The IgG1 serum levels were within 1 dilution for the four vaccine candidates. Only the control mice immunized intranasally with C. trachomatis EB To further define the specificity of the antibody response, serum samples were tested by Western blotting against C. trachomatis EB. As shown in Fig. 2 , the serum of the mice inoculated with SDS-MOMP and Z3-14-MOMP reacted mainly with MOMP. On the other hand, the serum from the mice immunized with OGP-MOMP and with the COMC reacted with MOMP, the 60-kDa crp, a 28-kDa component, and lipopolysaccharide (LPS). A distinct band was also observed at 10.5 kDa in the sera from the mice inoculated with the OGP-MOMP. The sera from the mice immunized with the COMC were the only serum samples that reacted with the affinitypurified 60-kDa hsp (data not shown).
The results of reacting the serum collected the day before challenge and 45 days after challenge against synthetic octameric peptides corresponding to the amino acid sequence of the C. trachomatis MoPn MOMP are shown in Fig. 3 . Overall, the broadest antibody response before challenge to the four variable domains (VDs) was obtained with the sera from the mice immunized with the COMC and the Z3-14-MOMP preparations. Serum collected the day before the challenge from animals immunized with SDS-MOMP reacted only with VD1. Antibodies from mice inoculated with OGP-MOMP weakly reacted against VD1 and VD2. On the other hand, serum from mice immunized with the Z3-14-MOMP and COMC had antibodies that reacted against the four VDs, as did the control immunized with C. trachomatis MoPn EB. The consensus amino acid sequences recognized by most of the sera included TGD and ASR in VD1, VGL in VD2, VGQ in VD3, and TISG in VD4.
Serum collected 45 days after the genital challenge showed, in general, an amnanestic response to the VD that originally reacted on the day before the challenge, for all the vaccine preparations. No significant reactivity to the VD4 region was observed with the sera from the mice immunized with the SDS-MOMP, and only a very weak response was observed in those inoculated with the OGP-MOMP preparation. Control mice immunized with ovalbumin showed a minimal antibody response to VD1 and VD2 following the intrabursal challenge, with no significant increase in the antibody levels to VD3 or VD4. The COMC-inoculated group and the control group immunized intranasally with EB had a strong antibody response to the four VDs on the day before the challenge, and no significant change in antibody levels was obtained following the challenge.
Antibodies in the genital tract were measured by ELISA following washings of the vagina twice with 20 l of PBS and a further 2ϫ dilution before testing (Table 1) . IgG-specific chlamydial antibodies were detected in the vaginas of all the four groups of immunized mice, with titers ranging from 64 to 128. The IgA titer of the three experimental groups immunized with purified MOMP was 16, while the IgA titer in the mice immunized with COMC was 128. The control mice inoculated intranasally with C. trachomatis EB had a vaginal IgA titer of 256.
T-cell response was determined in the groups of mice immunized with SDS-MOMP and with COMC (Table 1) . With EB as the antigenic stimulus, a significant proliferative response was observed in the two groups that closely paralleled the response obtained with the control mice inoculated intranasally with C. trachomatis MoPn EB. For example, the stimulation index (cpm of the sample stimulated with EB/cpm of the sample stimulated with medium) was 60 and 39 for the mice immunized with the SDS-MOMP and the COMC preparations, respectively, and 14 for the control mice inoculated with ovalbumin. The mice immunized intranasally with EB had a stimulation index of 215.
The controls inoculated with ovalbumin and the group of mice that was sham immunized and not challenged had no chlamydia-specific antibodies and no significant T-cell proliferative response to the EB on the day before the challenge ( Table 1) .
Course of the infection following the intrabursal challenge. The results of the vaginal cultures obtained at weekly intervals following the intrabursal challenge are shown in Table 2 . Overall, the most significant level of protection was observed in the animals immunized with COMC. In the control group inoculated with ovalbumin, 83% (40 of 48) of the mice had a positive culture during the 6 weeks of observation, while only 25% (4 of 20) of the animals immunized with COMC shed C. trachomatis vaginally (P Ͻ 0.05). Furthermore, the ovalbumin-inoculated mice had positive cultures up to 5 weeks following the challenge, while the group immunized with COMC had positive cultures only during the first 2-week postchallenge. In addition, the ovalbumin-inoculated mice shed a significantly higher number of infectious particles than did the COMC-immunized group.
Of the three groups immunized with SDS-MOMP, OGP-MOMP and Z3-14-MOMP, there were no significant differences compared with the ovalbumin-inoculated group regarding the total number of mice shedding following the challenge. The length of the shedding was, however, shorter in these three groups-3 to 4 versus 5 weeks-and the number of IFU for each mouse was lower in the group immunized with OGP-MOMP for the cultures collected during the 3rd week.
As expected, the positive controls immunized intranasally with C. trachomatis MoPn EB had very strong protection. Only 3% (1 of 35) of the animals shed vaginally and only during the 1st week postchallenge. In addition, the number of IFU was significantly lower. All the mice in the sham-immunized, nonchallenged group remained negative throughout the experiment.
Fertility studies. The results of the fertility studies are shown in Table 3 . Of the control sham-immunized, nonchallenged mice, 81% (17 of 21) were bilaterally fertile in contrast to the ovalbumin-inoculated, C. trachomatis-challenged group, in which only 23% (11 of 48) of the mice were bilaterally fertile (P Ͻ 0.05). Mice immunized intranasally with the C. trachomatis MoPn EB were protected, as shown by the fact that 94% (33 of 35) of the animals had bilateral pregnancies. On the other hand, of the four groups inoculated with C. trachomatis acellular vaccines, only those immunized with COMC had a bilateral fertility rate of 70% (14 of 20), which was not statistically significant different from the rate for the control shamimmunized, nonchallenged group (P Ͼ 0.05). The groups immunized with SDS-, OGP-, and Z3-14-MOMP had fertility rates that were significantly lower than that of the control group (P Ͻ 0.05).
We also calculated the average number of embryos per mouse for each group of animals. As shown in Table 3 , the average number of embryos was 5.9 in the control sham-immunized, nonchallenged group and 6.4 and 5.1 in the C. trachomatis MoPn EB-and COMC-immunized animals, respectively (P Ͼ 0.05). On the other hand, a significant decrease (P Ͻ 0.05) in the number of embryos was observed in the three groups immunized with SDS-, OGP-and Z3-14-MOMP.
DISCUSSION
Attempts to produce a vaccine to protect against C. trachomatis ocular infections were initiated several decades ago (17) . Based on trials in humans and monkeys, some investigators reported that individuals vaccinated with the whole organism were protected when subsequently challenged, while others developed worse symptoms than those occurring in the nonvaccinated controls (17) . The implication of these observations was that most likely, a component present in the whole organism predisposed the individual to a hypersensitivity reaction upon reexposure. Based on this assumption, recent attempts have been made at producing acellular vaccines with only purified chlamydial antigens. MOMP appears to be the best candidate for an acellular vaccine, since it is surface exposed, accounts for almost 60% of the outer membrane protein mass, and is strongly antigenic (2, 3, 8, 9, 41) . Stephens et al. (34), based on the comparison of the DNA and amino acid sequence of the L2, B, and C C. trachomatis serovars, showed that this protein has four VDs interspersed with five constant domains. The same overall molecular structure has now been confirmed for all human strains and the MoPn biovar (13, 14, 47) . The four VDs identified in MOMP elicit neutralizing antibodies with serovar, subgroup, and subspecies specificities, while Tcell epitopes have been mapped throughout the molecule (20, 23, 25, 26, 35) . However, efforts to vaccinate with purified C. trachomatis MOMP or peptides corresponding to the variable domains of MOMP have so far resulted in very limited success. For example, Taylor et al. (39) immunized monkeys with SDS-extracted MOMP and cholera toxin as an adjuvant in an attempt to induce protection against an ocular challenge. They observed that although there was a transient decrease in the inflammatory response, no reduction in the duration or intensity of the infection occurred. Tuffrey et al. (40) immunized mice with a recombinant serovar L1 MOMP expressed in Escherichia coli and purified with SDS and subsequently challenged the animals in the ovarian bursae or intravaginally with the human serovar F. Overall, although they observed in some groups a decrease in the severity of the salpingitis and in others a decrease in shedding, they were not able to demonstrate protection against infertility. Similarly, Batteiger et al. (1) immunized guinea pigs with the SDS-extracted MOMP of the Chlamydia psittaci agent of guinea pig inclusion conjunctivitis (GPIC) and observed no difference with the control nonimmunized animals following an intravaginal challenge. Also, Su et al. (36) inoculated mice with a synthetic oligopeptide corresponding to the C. trachomatis MOMP, containing a common T-helper and neutralizable B-cell epitopes, and detected no differences between the immunized and the control mice regarding colonization, shedding, or duration of the infection.
These investigators have proposed that the inability of these preparations to induce protective immunity was most likely due to the loss of conformational epitopes in MOMP. Alternatively, the need for additional chlamydial antigens and the inadequacy of the immunization protocols to induce a protective response in the mucosa were considered possible explanations for the failure of these approaches. In this respect, it is interesting that up to now, the most successful results with an acellular chlamydial vaccine were reported by Tan et al. (38) , who used an outer membrane preparation from C. psittaci. This preparation was found by electron microscopy to maintain the overall structure of an EB and by electrophoresis to contain the MOMP, the 60-kDa crp, and the LPS. When Tan et al. (38) immunized sheep with this preparation, they obtained protection against abortion following a subcutaneous challenge with the infectious organisms. On the other hand, Batteiger et al. (1) immunized guinea pigs with an outer membrane preparation, obtained like one of our MOMP immunogens with Sarkosyl and OGP, challenged the animals intravaginally with the C. psitacci GPIC, and observed a decrease in the quantity of shedding but not in the duration of the infection. This preparation was determined to contain mainly MOMP in addition to other components, including proteins at 84, 72, 61, 47, 35, and 33 kDa and LPS.
Here, we have followed a protocol similar to the one reported by Tan et al. (38) to prepare an acellular vaccine from C. trachomatis MoPn and have shown that immunization with this preparation protects mice against infection and infertility following an intrabursal challenge. In contrast, purified C. trachomatis MoPn MOMP extracted using three different protocols with an anionic (SDS), a nonionic (OGP) and a zwitterionic (Z3-14) detergent failed for the most part to protect the mice against a genital challenge. The fact that the COMC was able to protect, while the purified MOMP preparations were not, could be ascribed to several factors, including the presence of antigens other than the MOMP in the COMC and the different immunization protocol used with this preparation (38) . Therefore, the possibility that a detergent-extracted MOMP preparation in conjunction with the immunization protocol described for COMC may be able to protect cannot be completely excluded until such a protocol is tested. In our opinion, however, the ability of the COMC to protect is most likely due to the preservation of conformational epitopes or to the accessibility of the protective epitopes on MOMP to the immune cells. Here, the use of glutaraldehyde as outlined by Tan et al. (38) may have helped to fix the structure of the purified COMC and thus to maintain the native conformational epitopes of the EB. In the purified MOMP preparations, the conformational protective epitopes may be destroyed during the extraction procedure or they may be blocked by the detergent so that they are not accessible to the immune system. In this respect, we have recently shown that in the mouse model, intraperitoneal inoculation with a neutralizing IgA monoclonal antibody to a conformational epitope of the C. trachomatis MoPn MOMP resulted in protection against a genital challenge (23). In contrast, another IgA monoclonal antibody to a linear epitope of the MOMP had only minimal protective ability. Finally, Whittum-Hudson et al. (46) have recently reported that oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen of C. trachomatis resulted in a limited protection against an ocular challenge. Thus, at this point, the question of which chlamydial components may be used as a vaccine to protect against infection and/or disease remains open.
The immunological mechanisms involved in protection against a chlamydial genital infection are poorly understood. Humoral and cell immune responses may be critical at different stages of the infection (41) . For example, antibodies may inhibit the entry of EB by blocking cellular receptors or by modifying the EB surface charge and hydrophobicity. The genital mucosa could respond to an infection producing secretory IgA antibodies that block the pathogen at the site of entry. EB could also be opsonized by IgG or be killed by an antibodydependent cellular cytotoxic attack. Furthermore, CD4
ϩ and CD8 ϩ T cells, phagocytes, and cytokines may clear the organism at later stages of the infection. In this respect, Morrison et al. (19) , using gene knockout mice, demonstrated that major histocompatibility complex class II-restricted T-cell responses are required for protective immunity against a genital infection. In their experiments, ␤2m Ϫ/Ϫ mice resolved a genital infection like the control immunocompetent animals, while CD4 Ϫ/Ϫ animals showed a delayed resolution and class II Ϫ/Ϫ mice were unable to control the infection. In addition, these authors reported that all animals that recovered from the primary infection had decreased shedding upon reinfection. These findings support the observations reported by Igietseme et al. (18) showing that persistently infected T-cell deficient nude mice could resolve an infection following the adoptive transfer of a CD4 ϩ Th-1 T-cell clone that secreted high levels of interleukin-2, tumor necrosis factor, and gamma interferon. Thus, CD4
ϩ T cells appear to play a significant role in controlling the infection. On the other hand, the role that CD8 ϩ T cells may have in a chlamydial infection remains controversial, with both in vitro and in vivo experiments from several laboratories yielding contradictory results (19, 24, 33) .
We detected significant levels of IgA antibodies in the genital tracts of the mice immunized with the COMC preparation and in those of the control group inoculated intranasally with EB, the two groups that were protected against infection and disease. These results further substantiate the observation reported by Brunham et al. (5) and our results with the anti-MOMP IgA monoclonal antibody (23) and suggest that in a genital infection, mucosal humoral immunity may be sufficient to protect against infection. Furthermore, if an intracellular pathogen such as Chlamydia is to be blocked before it can infect a cell and thus produce sterilizing immunity, a vaccine will have to induce antibodies or other factors that are at the site of entry. Antibodies can neutralize infectivity on mucosal surfaces before a pathogen infects a cell, while the effector mechanisms of cell-mediated immunity can operate only after cells are infected. This may be different than the requirements to control an already established infection, in which the cellmediated immune response may be sufficient to eradicate the organism (28, 29) . In addition, in the case of a chlamydial genital infection, protection against long-term disease, e.g., infertility, ectopic pregnancy or chronic abdominal pain, may be achieved with a vaccine that does not necessarily protect against the infection. This would not be surprising, since most human vaccines protect against disease but not against infection (30).
We have analyzed the response to the different MOMP preparations, using octameric synthetic peptides. This technique is quite powerful, since it allows the determination at the molecular level of the antigenic sites able to induce a humoral immune response. However, an obvious shortcoming of this approach is that it does not detect conformational epitopes. In spite of this shortcoming, our results show that the four preparations tested elicited different immune responses. Overall, reactivity to VD1 was observed in all the groups of animals, although it was very weak in those immunized with OGP-MOMP, and reactivity to VD2 was found in all groups except those inoculated with SDS-MOMP. Antibodies to all four VDs were present only in the control mice that were intranasally immunized with EB and in the groups that were inoculated with the Z3-14-MOMP and the COMC preparations. In this respect, Batteiger et al. (1) , using recombinant fragments corresponding to the four VDs of the C. psittaci GPIC MOMP, tested the sera from guinea pigs immunized with SDS-MOMP and OGP-MOMP and from guinea pigs that had recovered from a genital infection and failed to observe significant differences in reactivity to any of the recombinant peptides corresponding to the four VDs. These differences with our results may be due to the types of methodologies used to detect antibodies to the VD, the use of octameric synthetic peptides versus recombinant peptide fragments, or to the differences in the immune responses elicited by the immunogens in mice in contrast to those in guinea pigs. Also, Su et al. (35) used the C. trachomatis MOMP from serovar A extracted with SDS to immunize six inbred strains of mice, with different H-2 haplotypes, and using synthetic peptides of 25 residues, they observed that VD1 and VD4 were the immunodominant regions. Again, this difference with our results, in which we did not detect reactivity to VD4 with the serum from the animals inoculated with the SDS-MOMP, may represent a true difference in the immunological response of the particular strain of mice or a technical artifact due to the methodologies that were utilized to detect the antibodies.
In conclusion, here we have shown for the first time that an acellular vaccine containing mainly the C. trachomatis MOMP, the 60-kDa crp, and LPS can protect against infection and against disease, e.g., infertility, following a genital challenge. This observation clearly establishes that inoculation with the whole organism is not necessary in order to protect against a C. trachomatis genital infection. A caveat with this model may be that the animals were challenged intrabursally. Thus, it could be argued that this immunization protocol may not protect against an intravaginal challenge, the natural route of infection, since the defense mechanisms operating in the lower and upper genital tract may be different. In our opinion, however, by inoculating intrabursally we are providing a more stringent proof of protection, since we are challenging the mice directly at the site where disease occurs, e.g., the oviduct, while bypassing sites such as the cervix, where most likely our immunization protocol will induce additional protective responses. Eventually, so that infertility and ectopic pregnancy can be protected against, the fallopian tube is the site at which the vaccine will have to block the spread of the infection. The ability to protect against an intravaginal challenge will nevertheless have to be experimentally tested before final conclusions can be reached. In addition, further work is necessary in order to identify and characterize the specific antigenic sites capable of inducing protection and the humoral and cellular components of the immune response that effect resistance against the infection.
